Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership
15.9.2026 12:16:00 EEST | Business Wire | Press release
Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/
Axo Longevity preventive health membership
The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21.
Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its first Latin American market, Peru. It is supported by more than 1,400 laboratory locations through certified partners including Randox, Sussex Pathology, Eurofins, MDI Limbach and Multilab. More than 19,000 people have joined the waitlist.
Its core membership, called Axo Longevity Care, costs 490 euros a year and includes two comprehensive blood panels analysing 100+ biomarkers each time, with an Axo Health Score and biological age, and personalised health plans. Membership starts from 190 euros a year. Members book a blood draw at a partner laboratory, receive results measured against optimal ranges rather than population averages, and retest six months later to track what has changed.
"I looked healthy. I trained, I ate well, I had no symptoms. If I had graded my health from one to ten, I would have said nine. In reality I was closer to a six," said Andrew McCarthy, Co-founder and CEO of Axo Longevity. "A full biomarker panel showed cardiovascular risk indicators that would have gone undetected for years. We’re building a service for what happens after the test."
Axo Longevity’s clinical team is led by Chief Medical Officer Dr. Niko Mihic, Medical Supervisor at Real Madrid FC, former Head of NBA Research in Europe and NFL Europe Medical Consultant, who was named by Forbes as one of Spain's 25 most influential healthcare providers. Andy Walshe, PhD, Executive Longevity Advisor, is the former Head of High Performance at Red Bull and currently advises the US, UK and Australian Olympic teams.
"Consumer health companies usually fail on operations, not on science," said Jon Soberg, CEO and Managing Partner of MS&AD Ventures. "Axo Longevity is live in six countries with Europe’s largest working laboratory network and members returning for repeat testing. That kind of infrastructure and engagement is much harder than launching a single market - and that’s exactly the kind of execution we look for."
Axo Longevity’s advisors include Michael Johnson, twelve time Olympic and World Champion; Mario Schlosser, co-founder of Oscar Health; Eric Solomon, former top exec at Google, YouTube, Spotify and Instagram; and Rosa Hamalainen, who helped scale Rupa Health.
"Europe has exceptional clinical infrastructure, but for consumers it is fragmented, and they might only be able to access it when they are sick," explains Sergio Tang, Co-founder and Chief Product and Growth Officer. "We are delivering a single membership experience that works seamlessly and equips people with a data-driven understanding of their health - and a clear action plan of exactly what to do next.
"This funding will allow us to grow our laboratory network, continue to develop our AI health copilot and wearable integrations, and expand our services into the Nordics, Italy and Portugal."
About Axo Longevity
Axo Longevity is a global preventive health membership, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its first Latin American market, Peru. Members receive comprehensive biomarker testing, a personalised health blueprint and ongoing tracking through Axo Longevity’s platform. Founded in 2025 by Andrew McCarthy, Sergio Tang and Octavia Seymour. Learn more at www.axolongevity.com
Imagery of the founders is available for download here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260910642125/en/
Contacts
Media Contact:
Kelly Marshall-Hill
The Tonic Communications
press@axolongevity.com
Office line - +44 1158248254
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 13:30:00 EEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 16:15:00 EEST | Press release
Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom